TrialX is Powering Global Studies with Multilingual Engagement, AI-Driven Trial Discovery & Remote Data Collection – on Earth and in Space
🦃 This holiday season, we’re especially grateful for partnerships that bring hope to patients and families. We are honored to power the AI-based clinical trial finder for ALK Positive, a patient-driven organization dedicated to improving the lives of ALK-positive patients worldwide. As Dr. Ken Culver, Executive Director and Medical Director at ALK Positive, shared: “Through our collaboration with TrialX, we’re empowering patients and families with a trusted resource to find and understand trials that may be right for them — helping transform what can often feel like an overwhelming search into an informed and hopeful journey.” Read the full press release. 🍂
What’s New at TrialX! 🚀
As commercial spaceflight expands, traditional Earth-dependent imaging is hitting its limits — from microgravity-driven physiological changes to communication delays and low bandwidth. If you’re a space enthusiast, space health researcher, or work in space health, diagnostics, telemedicine or clinical research – watch this webinar – to explore how imaging can function autonomously in zero-connectivity, high-risk environments and how these breakthroughs are shaping remote and decentralized care on Earth. Learn more.
📢 UPCOMING CONFERENCE
We’re proud to sponsor the 17th Annual SCOPE Summit and look forward to seeing you at Booth #225 this February. Wes Martz, Senior Director of Client Services, and Beth Dickson, VP of Business Development, will be onsite to share how our enterprise patient recruitment platform and remote data collection solutions are transforming clinical research.
❇️ PRODUCT HIGHLIGHTS
We’re proud to facilitate more inclusive clinical trials by helping top sponsors and study teams communicate with participants in multiple languages—equipping them with the tools to reach the right participants, in the right language, across local to global studies. Learn how we’re breaking down barriers to boost trial awareness and participation.
November was Epilepsy Awareness Month, and we are proud to support Montefiore Medical Center and the University of Cincinnati in launching the FORETELL-Epilepsy app, an NIH-funded initiative designed to advance seizure forecasting and improve patient care. The app enables adults living with epilepsy to contribute real-world data through daily diaries of seizures, mood, and stress, while also integrating with wearable devices to track heart rate and sleep. The app is now live on both app stores, with enrollment currently underway. Learn more.
Space missions demand health monitoring in environments with limited connectivity and extreme conditions—where traditional tools often fall short. TrialX Space Health Systems is an offline-capable, AI-powered platform that collects and analyzes diverse datasets, from wearables to genomics, even beyond Earth’s grid. Remote health research is possible, wherever the mission goes. Learn More.
🎤️ UNSUNG BUT IMPACTFUL VOICES OF CLINICAL RESEARCH HEROES
Meaningful progress in clinical research often comes from those quietly connecting patients with the right studies. This month, our Unsung But Impactful Voices series features Thomas (Tom) Hohing of the University of Pennsylvania, whose work centers on clarity, trust, and genuine connection. His efforts help make studies more accessible and inclusive. Read the full interview.
RECENT CURETALKS 
🧬 FEATURED CLINICAL STUDIES
Powered by TrialX
The Snacks and Satiety Study: Researchers at Indiana University are testing how different snack bars affect fullness and how much people eat at their next meal. Adults ages 18–65 will try two types of bars, track their food intake, and attend in-person visits to measure appetite and eating patterns. The goal is to understand how snack nutrition and eating habits influence satiety.
The Taste Dysfunction Study: Researchers at the Monell Chemical Senses Center are examining how taste works in adults with and without taste loss. Participants complete a brief questionnaire and simple taste tests during a single 15–60 minute visit. The goal is to better understand taste disorders and develop a screening kit that can identify taste dysfunction.
The AVALON Study: Researchers are testing VTP-1000, an investigational immunotherapy designed to help adults with celiac disease tolerate accidental gluten exposure. This Phase 1 trial evaluates safety and how the treatment affects immune response. Participants complete screening, receive study medication or placebo, and take part in a monitored gluten challenge.
The SeizureWise Study: Researchers are testing whether a wearable device can forecast seizure risk in people with epilepsy. Participants use a wrist sensor that tracks physiological and behavioral patterns to help build a personalized prediction tool. The study compares those who receive seizure-risk feedback with those who don’t to assess accuracy and potential improvements in daily functioning and quality of life.
🌎 AROUND THE WEB
💊 Stress signal: AI researchers identify a biomarker for chronic stress using CT scans.
🌱 Space survivor: Moss spent 9 months outside the ISS, still able to grow here on earth.
💉 Insulin rethink: A personalized oral insulin pill reaches a key early-trial milestone
🚀 25 years in orbit: NASA highlights 25 years of scientific discoveries aboard the International Space Station.
‼️ NOTEWORTHY
This Thanksgiving, we’re grateful for our community — for your trust, collaboration, and continued engagement with our work. Whether you’re a client, partner, colleague, or supporter, we appreciate the opportunity to learn, innovate, and grow together.
At TrialX, we strive to revolutionize the way clinical trials are conducted on earth and in space, by focusing on innovative solutions to streamline patient recruitment and remote data collection. Stay tuned for more updates as we continue to look up to the Moon & Mars!
